Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Liver Diseases Therapeutics Market Grown from 2024 to 2025?

The market for therapeutics for liver diseases has seen a marked increase in size in the past few years. It is projected to expand from a valuation of $14.16 billion in 2024 to $15.23 billion the following year, reflecting a compound annual growth rate (CAGR) of 7.6%. Several factors have contributed to this growth during the historic period, including the high incidence rate of liver diseases, drinking habits, advances in diagnostic technology, the prevalence of obesity and metabolic syndromes, consciousness and screening initiatives, and governmental efforts to manage hepatitis.

What Growth Rate Is Anticipated for the Liver Diseases Therapeutics Market in the Coming Years?

Exciting progress is anticipated within the therapeutics market for liver diseases within the next few years, with an expected surge to $20.78 billion by 2029, signalling a compound annual growth rate (CAGR) of 8.1%. This upswing throughout the forecast window is attributed to several factors, including enhanced focus on precision medicine, innovations in RNA therapeutics and increasingly pointed focus on fibrosis treatments. The rise of patient advocacy and support groups, the development of hepatitis vaccines, and enhanced regulatory support for seldom-used drugs are also driving growth. Significant trends we’ll see unfold during the forecast period include treatment advancements for hepatitis C, the rise of novel therapies for liver fibrosis, the investigation of immunotherapies, the application of telemedicine and remote monitoring, as well as an emphasis on nutritional interventions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

Who Are the Leading Companies in the Liver Diseases Therapeutics Market?

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

What Are the Key Drivers of the Liver Diseases Therapeutics Market?

The increase in liver disease cases is anticipated to boost the liver disease therapeutics market’s expansion in the future. Various treatments fall under the umbrella of these therapeutics, which combat afflictions of the liver, a broad term for any malaise disrupting this organ’s normal function. For example, data from the Office for Health Improvement and Disparities, a government department in the UK, revealed in April 2024 that the death rate due to liver disease in individuals less than 75 years old in England had escalated to 21.4 per 100,000 population in 2022. Males were particularly hard hit, with 6,664 early deaths compared to 3,929 for women. Consequently, the escalating incidence of liver diseases is a crucial factor propelling the liver disease therapeutics market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp

What Are the Key Market Segments in the Liver Diseases Therapeutics Industry?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

What Are the Latest Trends in the Liver Diseases Therapeutics Market?

A prominent trend gaining traction in the liver disease therapeutics market is strategic partnerships. Many leading firms in the liver disease therapeutics segment are forming alliances to solidify their market standing. Case in point, Aligos Therapeutics Inc., a clinical-stage biopharmaceutical enterprise based in the U.S, joined forces with Merck & Co, another U.S-based company specializing in liver disease therapeutics, in January 2022. This partnership aims at the discovery and development of oligonucleotide treatments for non-alcoholic steatohepatitis.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

What Are the Key Regional Markets in the Liver Diseases Therapeutics Industry?

North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7969

This Report Delivers Insight On:

1. How big is the liver diseases therapeutics market, and how is it changing globally?

2. Who are the major companies in the liver diseases therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the liver diseases therapeutics market right now?

4. Which products or customer segments are growing the most in the liver diseases therapeutics market?

5. What factors are helping or slowing down the growth of the liver diseases therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model